Literature DB >> 14023124

Status of disease due to unclassified mycobacteria. A statement of the Subcommittee on Unclassified Mycobacteria of the Committee on Therapy.

R F CORPE, E H RUNYON, W LESTER.   

Abstract

Entities:  

Keywords:  MYCOBACTERIUM; TUBERCULOSIS, PULMONARY

Mesh：

Year:  1963        PMID： 14023124     DOI： 10.1164/arrd.1963.87.3P1.459

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN： 0003-0805


× No keyword cloud information.
  8 in total

1.  Letter: Coexistence of photochromogenic mycobacteria and carcinoma.

Authors:  Z K Epners
Journal:  Can Med Assoc J       Date:  1975-05-17       Impact factor: 8.262

Review 2.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

3.  [Atypical mycobacteria as pathogens in the cervical lymph node tuberculosis of children].

Authors:  K H Schröder
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1968

4.  Treatment of unclassified mycobacterial infection of the lungs.

Authors:  K P Goldman
Journal:  Thorax       Date:  1968-01       Impact factor: 9.139

5.  Hodgkin's disease complicated by infection with Mycobacterium kansasii.

Authors:  J Harris; R Alexanian; E M Hersh; W Leary
Journal:  Can Med Assoc J       Date:  1969-08-23       Impact factor: 8.262

6.  Mycobacterial lymphadenitis in childhood.

Authors:  A Mackellar; H B Hilton; P L Masters
Journal:  Arch Dis Child       Date:  1967-02       Impact factor: 3.791

7.  Properties of beta-lactamases produced by three species of mycobacteria.

Authors:  J E Kasik; L Peacham
Journal:  Biochem J       Date:  1968-05       Impact factor: 3.857

Review 8.  Clinical Features, Histopathology and Differential Diagnosis of Sarcoidosis.

Authors:  Claudio Tana; Iginio Donatiello; Alessandro Caputo; Marco Tana; Teresa Naccarelli; Cesare Mantini; Fabrizio Ricci; Andrea Ticinesi; Tiziana Meschi; Francesco Cipollone; Maria Adele Giamberardino
Journal:  Cells       Date:  2021-12-26       Impact factor: 6.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.